Employing Synthetic T-cell Biology to Target AML without On-Target/Off-Cancer Toxicity.

Ideal targets for chimeric antigen receptor T-cell therapy for acute myeloid leukemia (AML) remain elusive. In this issue of Blood Cancer Discovery , Richards and colleagues explore CD93 as a potential AML target antigen, and devise an approach to mitigate "on-target/off-cancer toxicity." See related article by Richards et al., p. 648 .